Loading...
•
Mar 31, 2022
Pulse Biosciences Q1 2022 Earnings Report
Pulse Biosciences reported financial results for the first quarter of 2022.
Key Takeaways
Pulse Biosciences reported first quarter 2022 revenue of $444 thousand. The company is prioritizing increasing CellFX System utilization at a subset of commercial clinics to establish commercial integration best practices.
Increased the average CellFX System commercial session utilization during Q1.
Appointed new commercial leadership and began initiation of the CellFX System utilization program in May.
Generated first quarter 2022 revenue of $444 thousand.
Completed one commercial sale of a CellFX System in the first quarter of 2022.
Forward Guidance
Pulse Biosciences is focused on increasing CellFX System utilization and indication expansion.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...